Friday, July 10, 2026

pharma · Major Depression Disorder · Major Depression Disorders

Mylan Specialty

Mylan Specialty clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

napa, USA HQ
233 Employees
NMPA registrant Type
Company details
Status
Public
HQ
napa, USA
Employees
233
Programs
4
Drugs
10
Patents
0
Intelligence · Clinical Programs

Mylan Specialty projects

4 ClinicalTrials.gov programs sponsored by Mylan Specialty.

Mylan Specialty has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. MYL-1603N-3001

    Mylan Pharma UK

    Major Depression Disorder

    phase 3 small molecule active

    1 trial
  2. MYL-1603N-3002

    Mylan Pharma UK

    Major Depression Disorders

    phase 3 small molecule active

    1 trial
  3. MR-130A-01

    Mylan Pharma UK

    Investigation of maintenance of ovulation inhibition after intentional application errors for indication of contraception in healthy subjects

    phase 2 small molecule active

    1 trial
  4. EPIN-IJS-1002

    Mylan Pharma UK

    Allergic reactions (Type 1), including anaphylaxis, idiopathic anaphylaxis or exercise-induced anaphylaxis

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Mylan Specialty have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.